Cencora Acquires Retina Consultants, Raises EPS Guidance

By Tamara Parker • Friday, January 03 15:15 • Permanent Link

Cencora, Inc. has completed its acquisition of Retina Consultants of America (RCA), a leading management services organization of retina specialists. The acquisition allows Cencora to build on its leadership in specialty, expand its MSO solutions, and drive differentiated value for stakeholders, including physicians and patients.

In light of this acquisition, Cencora has updated its fiscal year 2025 financial guidance. The company now expects adjusted diluted earnings per share (EPS) to be in the range of $15.15 to $15.45, raised from the previous range of $14.80 to $15.10.

Cencora is a leading global pharmaceutical solutions organization with more than $290 billion in annual revenue and is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500.

This acquisition is expected to have a significant impact on Cencora's performance, as evidenced by the upward adjustment in the EPS guidance range for fiscal year 2025. Following these announcements, the company's shares moved 2.8%, and are now trading at a price of $231.04. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.